跳至主要内容
临床试验/NCT00415077
NCT00415077终止不适用

A Prospective Comparison of Photorefractive Keratectomy (PRK), PRK With Mitomycin-C and Laser Subepithelial Keratomileusis (LASEK) in the Treatment of Moderate and High Myopia

Walter Reed Army Medical Center2 个研究点 分布在 1 个国家目标入组 960 人开始时间: 2004年6月最近更新:
适应症

试验速览

阶段
不适用
状态
终止
入组人数
960
试验地点
2
主要终点
Efficacy in terms of uncorrected visual acuity and post operative refraction. Safety in terms of maintenance of best spectacle corrected acuity within 2 lines of preoperative levels.

研究概览

简要总结

The purpose of this study is to assess whether there is a significant difference in visual outcomes or corneal haze after surface ablation for moderate and high myopia in active duty service members treated with PRK, Mitomycin-C (MMC) PRK and LASEK.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
None

入排标准

年龄范围
21 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Informed consent.
  • Normal, healthy, active duty adults age 21 years or older. The lower age limit of 21 years is intended to ensure documentation of refractive stability.
  • Manifest refractive spherical equivalent of greater than -4.00 diopters (D) up to -10.00 D.
  • Best spectacle corrected visual acuity of 20/20 or better in both eyes.
  • Demonstrated refractive stability, confirmed by clinical records. Neither the spherical nor the cylindrical portion of the refraction may have changed more than 0.50D during the 12-month period immediately preceding the baseline examination, as confirmed by clinical records.
  • Both eyes must fall in the same refraction group and there must be less than 1 D difference between eyes.
  • Soft contact lens users must have removed their lenses at least 2 weeks before baseline measurements. Hard contact lens users (PMMA or rigid gas permeable lenses) must have removed their lenses at least 4 weeks prior to baseline measurements and have 2 central keratometry readings and 2 manifest refractions taken at least 1 week apart that do not differ by more than 0.50 D in either meridian.
  • Access to transportation to meet the follow-up requirements.
  • Available for evaluation during the 1-year follow-up period.
  • Consent of the subject's command to participate in the study.

排除标准

  • Female subjects who are pregnant, breast-feeding or intend to become pregnant during the study. Women of childbearing age will take a urine pregnancy test before starting this study.
  • Residual, recurrent or active ocular diseases or corneal abnormalities in either eye such as keratoconus, iritis, uveitis, keratoconjunctivitis sicca, vernal conjunctivitis, lagophthalmos, corneal scarring, glaucoma, previous steroid responder, occludable chamber angles, visually significant cataracts.
  • Medical condition(s), which, in the judgment of the investigator, may impair healing, including but not limited to: collagen vascular disease, autoimmune disease, immunodeficiency diseases, and ocular herpes zoster or simplex.
  • Concurrent topical or systemic medications that may impair healing, including corticosteroids, antimetabolites, isotretinoin (Accutane), amiodarone hydrochloride (Cordarone) and/or sumatripin (Imitrex).
  • Any physical or mental impairment that would preclude participation in any of the examinations.
  • Prior refractive or ocular surgery.

结局指标

主要结局

Efficacy in terms of uncorrected visual acuity and post operative refraction. Safety in terms of maintenance of best spectacle corrected acuity within 2 lines of preoperative levels.

时间窗: 12 months after surgery

次要结局

未报告次要终点

研究者

申办方类型
Fed

研究点 (2)

Loading locations...

相似试验

A Comparison of Photorefractive Keratectomy (PRK),... | 临床试验